retatrutide phase 2 trial type 2 diabetes weight loss 2024 Lilly's triple agonist, retatrutide, successful in two additional 3 obesity trials, delivering significant improvements in and A1C Retatrutide TRIUMPH-4 Results: Are We

While published subgroup analyses focus primarily on diabetes status rather than age categories, the available data allows for some preliminary observations about younger participants

Its worth noting that because retatrutide targets three hormone pathways instead of one or two, some people in trials experienced more pronounced digestive side effects compared to other weight loss medications

But within those medications, there is an important distinction: standard-dose protocols are designed for stronger appetite suppression and more traditional weight loss titration, while microdose protocols use lower-dose strategies intended to be gentler, more gradual, and often easier to tolerate

2026 Jun 11 [cited 2026 Jun 15]

Dao K, Shechtman S, Weber-Schoendorfer C, Diav-Citrin O, Murad RH, Berlin M, et al

Next-generation combinations (GLP-1 + GIP, triple agonists with glucagon, GLP-1 + amylin) are even more powerful and represent the future of metabolic therapeutics - potentially 25-30% body weight reduction with profound improvements in liver fat, insulin sensitivity, and cardiovascular markers